Market closedNon-fractional
Axsome Therapeutics/AXSM
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
AXSM
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New York, United States
Employees
569
Website
www.axsome.com
AXSM Metrics
BasicAdvanced
$3.7B
Market cap
-
P/E ratio
-$6.39
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$3.7B
Beta
1.25
Financial strength
Current ratio
3.197
Quick ratio
3.005
Long term debt to equity
130.276
Total debt to equity
131.515
Interest coverage (TTM)
-46.49%
Management effectiveness
Return on assets (TTM)
-32.77%
Return on equity (TTM)
-231.68%
Valuation
Price to revenue (TTM)
14.59
Price to book
26.28
Price to tangible book (TTM)
47.15
Price to free cash flow (TTM)
-18.94
Growth
Revenue change (TTM)
73.58%
Earnings per share change (TTM)
68.72%
3-year earnings per share growth
33.71%
What the Analysts think about AXSM
Analyst Ratings
Majority rating from 16 analysts.
AXSM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$75M
4.76%
Net income
-$68M
-30.73%
Profit margin
-91.18%
-33.88%
AXSM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.54
-$1.32
-$2.08
-$1.44
-
Expected
-$1.22
-$1.20
-$1.17
-$1.20
-$1.33
Surprise
25.98%
9.67%
77.59%
19.56%
-
AXSM News
AllArticlesVideos
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GlobeNewsWire·4 weeks ago
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
GlobeNewsWire·4 weeks ago
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $3.7B as of July 04, 2024.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of July 04, 2024.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Axsome Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.